Key result
COX-2 inhibition by rofecoxib completely abolished the antithrombotic and anti-atherosclerotic effects of aspirin during long-term treatment in cholesterol-fed rabbits.
Why the study?
Does the addition of rofecoxib to aspirin attenuate aspirin's antithrombotic and anti-atherosclerotic effects in a cholesterol-fed rabbit model?
RCT
randomly assigned
Does the addition of rofecoxib to aspirin attenuate aspirin's antithrombotic and anti-atherosclerotic effects in a cholesterol-fed rabbit model?
In a hypercholesterolemic rabbit model, the selective COX-2 inhibitor rofecoxib completely abolished the antithrombotic and anti-atherosclerotic benefits of aspirin.
Answers are grounded in this paper and cite their sources.
Raises caution for COX-2 inhibitor-aspirin combinations; leaves open relevance to human atherosclerosis and thrombosis.
BACKGROUND AND PURPOSE: Most patients at elevated cardiovascular risk receive long-term aspirin (ASA) anti-platelet treatment. The present study specifically addresses the pharmacological interactions between selective COX-2 inhibitors and ASA and the possible consequences for the thrombotic risk during long-term treatment. EXPERIMENTAL APPROACH: New Zealand white rabbits were fed a standard laboratory diet supplemented with 1% cholesterol (CON) for 12 weeks. Age-matched control rabbits were fed the same standard diet without addition of cholesterol (SD). Rabbits were randomly assigned to one of the following groups: rofecoxib (ROFE, 25 mg·kg⁻¹, bid), acetylsalicylic acid (ASA, 5 mg·kg⁻¹, bid) or a combination of both (ASA + ROFE). At the end of the feeding period, the severity of atherosclerotic plaque formation was assessed in the aorta. Thrombus formation was assessed in the left carotid artery using a modified Folts procedure. KEY RESULTS: Treatment of cholesterol-fed rabbits with ASA significantly reduced plaque formation. This reduction in lesion size was not observed in animals treated with the combination of rofecoxib and ASA. In the modified Folts model, treatment with either rofecoxib or ASA increased the total blood flow above that of untreated animals. This increase was statistically significant in the case of ASA, while cotreatment with rofecoxib abolished this ASA effect completely and reduced the total flow rate to the levels seen in untreated hypercholesterolaemic controls. CONCLUSIONS: COX-2 inhibition by rofecoxib attenuates the antithrombotic and anti-atherosclerotic effects of ASA during long-term treatment in cholesterol-fed rabbits.
No takes yet. Share an insight, caveat, or question.
Kaber et al. (2011) conducted an RCT in Atherosclerosis and thrombosis. Rofecoxib and Acetylsalicylic acid (ASA) combination vs. ASA alone, rofecoxib alone, or untreated controls was evaluated on Severity of atherosclerotic plaque formation in the aorta and thrombus formation in the left carotid artery. COX-2 inhibition by rofecoxib completely abolished the antithrombotic and anti-atherosclerotic effects of aspirin during long-term treatment in cholesterol-fed rabbits.
Synapse has enriched 10 related papers. Consider them for comparative context: